Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste.
Bioavailability
Cyclodextrin
Griseofulvin
Nanosponges
Taste masking
Journal
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
ISSN: 1319-0164
Titre abrégé: Saudi Pharm J
Pays: Saudi Arabia
ID NLM: 9705695
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
21
10
2019
accepted:
29
01
2020
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
21
3
2020
Statut:
ppublish
Résumé
The aim of this study was the development of griseofulvin (GRI) loaded β-cyclodextrin (β-CD) based nanosponges for bitter taste masking, improving dissolution rate and oral bioavailability. Plain NS (NS1 NS2 and NS3) were fabricated by reacting β-CD with the cross-linker diphenyl carbonate at different molar ratios (1:2, 1:4 and 1:6, respectively) using ultrasonication method. The NS2 provided both highest %yield and GRI solubilization enhancement. Thus, the drug was loaded in NS2 at different NS2: drug weight ratios in presence or absence of 0.25%w/w polyvinylpyrolidone (PVP k30). The GRI loaded NS (F1) that provided highest drug loading capacity and entrapment efficiency (47.20
Identifiants
pubmed: 32194337
doi: 10.1016/j.jsps.2020.01.016
pii: S1319-0164(20)30024-4
pmc: PMC7078523
doi:
Types de publication
Journal Article
Langues
eng
Pagination
349-361Informations de copyright
© 2020 Published by Elsevier B.V. on behalf of King Saud University.
Références
Acta Pharm. 2013 Sep;63(3):335-58
pubmed: 24152895
J Biotechnol. 2004 Sep 30;113(1-3):151-70
pubmed: 15380654
Drug Dev Ind Pharm. 1998 Jun;24(6):583-7
pubmed: 9876628
AAPS PharmSciTech. 2010 Mar;11(1):27-35
pubmed: 20013079
Pak J Pharm Sci. 2018 Sep;31(5(Supplementary)):2069-2076
pubmed: 30393214
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 1;850(1-2):318-26
pubmed: 17196449
Chem Pharm Bull (Tokyo). 2003 Aug;51(8):914-22
pubmed: 12913228
Chem Pharm Bull (Tokyo). 2007 Dec;55(12):1713-9
pubmed: 18057745
AAPS PharmSciTech. 2018 Jul;19(5):2358-2369
pubmed: 29869305
Drug Dev Ind Pharm. 2018 Aug;44(8):1243-1253
pubmed: 29452493
J Pharm Sci. 1983 Oct;72(10):1189-91
pubmed: 6644570
Beilstein J Org Chem. 2012;8:2091-9
pubmed: 23243470
J Pharm Sci. 1996 Oct;85(10):1017-25
pubmed: 8897265
AAPS J. 2013 Apr;15(2):608-17
pubmed: 23456436
J Pharm Bioallied Sci. 2011 Jul;3(3):417-25
pubmed: 21966164
Biopharm Drug Dispos. 2009 Dec;30(9):524-31
pubmed: 19823969
J Control Release. 2014 Sep 28;190:31-2
pubmed: 25356469
AAPS PharmSciTech. 2011 Mar;12(1):279-86
pubmed: 21240574
J Pharm Pharmacol. 1975 Jan;27(1):48-9
pubmed: 235616
Pharm Dev Technol. 2013 May-Jun;18(3):619-25
pubmed: 22235935
Mol Pharm. 2008 Jul-Aug;5(4):505-15
pubmed: 18672949
J Pharmacol Pharmacother. 2010 Jul;1(2):87-93
pubmed: 21350616
Molecules. 2014 Sep 09;19(9):14066-79
pubmed: 25207713
J Pharm Pharmacol. 2004 Nov;56(11):1379-87
pubmed: 15525444
AAPS PharmSciTech. 2016 Feb;17(1):99-105
pubmed: 26288942
Int J Pharm. 2012 May 30;428(1-2):152-63
pubmed: 22388054
AAPS PharmSciTech. 2017 Jul;18(5):1728-1738
pubmed: 27757921
Molecules. 2016 Oct 29;21(11):
pubmed: 27801880
Bioorg Med Chem. 2008 Sep 15;16(18):8403-12
pubmed: 18771929
Pharm Res. 1995 Mar;12(3):413-20
pubmed: 7617530
Drug Dev Ind Pharm. 2017 Dec;43(12):2076-2084
pubmed: 28845699
Int J Pharm. 2005 Jun 13;297(1-2):213-22
pubmed: 15885935
Eur J Pharm Sci. 2014 Jun 16;57:152-63
pubmed: 24486482
Pediatr Dermatol. 2000 Jul-Aug;17(4):304-9
pubmed: 10990583
Drug Dev Ind Pharm. 2015;41(12):2029-36
pubmed: 26006328
AAPS PharmSciTech. 2005 Oct 14;6(2):E329-57
pubmed: 16353992
J Control Release. 2008 Jul 2;129(1):49-58
pubmed: 18456362
Polymers (Basel). 2018 Sep 19;10(9):
pubmed: 30960963